Natco Pharma Limited

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange regarding the conclusion of US FDA inspection at its Visakhapatnam, Andhra Pradesh, Finished Dosage Formulations (FDF) Unit, with 4 observations, which the company believes are procedural in nature and will be addressed within stipulated timelines.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange about the schedule of an investor meeting to be held on 24th August 2026 in Singapore, organised by Nuvama Wealth and ICICI Securities Limited.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange about Investor Presentation, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange about the transcript of the earnings conference call held on August 14, 2026. The company recorded consolidated total revenues of INR794.4 crores in quarter 1 FY27 compared to INR1,390.6 crores in the corresponding quarter last year. EBITDA, including other income for the quarter, stood at INR245.7 crores with EBITDA margin of 30.9%. Consolidated profit after tax stood at INR206.5 crores compared to INR269 crores in quarter 4 of FY26.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange about the schedule of an investor meeting to be held on 19th and 21st August 2026, organised by Nuvama Wealth Limited and ICICI Securities Limited.

Natco Pharma Limited

Natco Pharma Limited has published un-audited financial results for the quarter ended June 30, 2026, and declared an interim dividend for the FY ending 2026-27.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange about the link of the recording of the earnings conference call held on August 14, 2026, for Q1 FY26-27.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange about the Q1 FY 27 Earnings Presentation for the Quarter ended 30th June, 2026.

Natco Pharma Limited

Natco Pharma Limited has declared an interim dividend of Rs.1.50 per equity share for the financial year 2026-27, with a record date of 20th August 2026 and payment starting from 26th August 2026.

Natco Pharma Limited

Natco Pharma Limited has submitted its financial results for the period ended June 30, 2026, and declared an interim dividend of Rs.1.50 per equity share. The company recorded a consolidated revenue of Rs.794.4 Crore and a profit after tax of Rs.206.5 Crore for Q1 FY27. The results show a decline in revenue and profit compared to the corresponding quarter last year, largely due to lower Lenalidomide revenue. The company has also acquired an additional 13.25% stake in Adcock Ingram Holdings Limited, taking its total holdings to 49%. The Board of Directors has approved the Notice for the 43rd Annual General Meeting and authorized the Chairman and Managing Director to fix the date and time of the meeting through video conference.

Natco Pharma Limited

Natco Pharma Limited

Natco Pharma Limited has received tentative approval from the US FDA for its Olaparib tablets, a generic version of AstraZeneca's Lynparza, for the indication in the approved labelling.

Natco Pharma Limited

Natco Pharma Limited has completed the acquisition of an additional 13.25% stake in Adcock Ingram Holdings Proprietary Limited, increasing its shareholding from 35.75% to 49%. The acquisition was completed through Natco Pharma South Africa Proprietary Limited, Natco's wholly owned subsidiary in South Africa.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange about actions taken or orders passed under the APGST & CGST Act, 2017, raising a tax demand of Rs. 21,34,729/-, interest of Rs 17,17,806/- and penalty of Rs.21,34,729/-.

Natco Pharma Limited

Natco Pharma Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026, confirming the dematerialization of securities and updating the records of the company.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 08, 2026, where the Board of Directors approved to acquire additional shareholding in Adcock Ingram Holdings Proprietary Limited, increasing its stake from 35.75% to 49%. The acquisition valued at ₹ 1,069 crores will take NATCO's shareholding in Adcock Ingram from 35.75% to 49%. Adcock Ingram has delivered a topline of US$ 423 million with an EBITDA of ~US$ 59 million for the period ending 9 months on March 31, 2026.

Natco Pharma Limited

Natco Pharma Limited has announced a change in management with Mr. Gnanadeva Chalapathy Gudipati being designated as Senior Vice President - Analytical Research & Development and Mr. Madhava Rao Karicherla as Vice President – Formulation Research & Development, effective July 6, 2026.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange about the retirement of Mr. Nadella Malleswara Rao, Vice President - Operations, Pharma Division Kothur, effective June 30, 2026.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in the securities of the Company will remain closed for Directors, Designated Persons, their immediate relatives, and all other connected persons from July 1, 2026, to 48 hours after the declaration of the Unaudited Financial Results for the quarter ending June 30, 2026.